CON at a glance
Concentra Group Holdings Parent, Inc. (CON, SEC CIK 2014596) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as September 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Concentra Group Holdings Parent, Inc. (CON) reported revenue of $2.2 billion (up 13.9% from FY2024) and net income of $166.4 million. Diluted EPS was $1.30.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Concentra Group Holdings Parent, Inc. (CON) shares worth $2.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ORTENZIO ROBERT A on August 3, 2026 of 130,000 shares at $31.84 per share.
- In the last 90 days, CON insiders reported 0 open-market purchases ($0) and 1 open-market sale ($4.1M) on Form 4, a net sale of $4.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.2B
- +13.9% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$4.1M
- 13F holders
- 31 funds
- $2.1B · −1 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: largest U.S. provider of occupational health services via 628 centers in 41 states, plus 411 onsite clinics in 44 states
- New emphasis: completed IPO July 2024 raising $516.5M net; separated from Select Medical via spin-off November 2024
- Strategic shift: transitioned from subsidiary within Select to independent public company; reverse stock split 1-for-4.295 in June 2024
- Notable metric: revenue grew 14% to $2.16B in 2025, employees not specified but support functions transitioned via TSAs post-IPO
- Unique fact: became large accelerated filer in 2026 due to public float exceeding $700M and now subject to Section 404(b) auditor attestation requirements
Risk Factors
- Regulatory/legal risk: Non-compliance with Credit Agreement leverage covenant could trigger default, accelerate $942.9M Term Loan due 2031, and restrict borrowings under $450M Revolving Credit Facility
- Macroeconomic threat: Inflation-driven labor cost increases in healthcare sector may pressure margins, though impact to date reported as not material
- Operational risk: Integration complexity and cash outflow risk from $333.3M acquisitions of Nova and Pivot Onsite Innovations in 2025
- Competitive risk: Expansion via strategic acquisitions of occupational health centers and onsite clinics crucial versus competitors in fragmented market
- Financial risk: High leverage with $942.9M Term Loan (interest rate 5.72%) plus $650M Senior Notes at 6.875%, with scheduled principal payments of $10.7M next 12 months
Management Discussion & Analysis
- Revenue $2,163.4M, up 13.9% YoY from $1,900.2M driven by acquisitions and organic patient visit growth
- Operating margin 15.4% vs 16.0% in prior year; net income margin 7.7% vs 8.8%; interest expense increased to $109.3M from $47.7M
- Best performing segment: occupational health centers, comprising 93% revenue in 2025; onsite health clinics fastest growth from 3% to 5% revenue share
- Repurchased 1.1M shares for $22.4M; voluntary debt repayment of $85M; capital expenditures increased depreciation to $75.8M from $67.2M
- Management notes increased reimbursement rates and patient volume for 2026; risks include regulatory changes and integration of acquisitions
AI summary of the CON 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Operating footprint: 633 occupational health centers and 415 onsite clinics as of June 30, 2026
- Occupational health centers: 91% of quarterly revenue versus 94% in 2025
- Onsite health clinics: 7% of quarterly revenue versus 4% in 2025
- Workers’ compensation: 46% of center visits and 66% of visit-related revenue
- Headwinds: labor shortages, rising employee costs, reimbursement pressure, regulation, cybersecurity, and economic conditions
Risk Factors
- No material changes from December 31, 2025 Form 10-K risk factors
- Carried-forward regulatory, legal, and compliance risks unchanged from annual filing
- Carried-forward operational and competitive risks unchanged from annual filing
- Carried-forward liquidity, debt, currency, and concentration risks unchanged from annual filing
AI summary of the CON 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO succession effective November 1, 2026: Matthew DiCanio becomes CEO and Keith Newton becomes Executive Chairman
- Tanner Newton, age 34, appointed Executive Vice President and CFO effective November 1, 2026
Item 7.01: Regulation FD Disclosure
- T. Newton appointed Executive Vice President and Chief Financial Officer
- Leadership change may affect financial reporting, capital allocation, and investor communications
Item EX-99.1: Item EX-99.1
- Tanner Newton appointed CFO effective November 1, 2026, succeeding Matt DiCanio
- DiCanio becomes president and CEO, marking a planned leadership succession
Item 1.01: Entry into a Material Definitive Agreement
- Company repurchased 1,000,000 shares for $34.65 million at $34.65 per share
- Purchase price reflected a 1% discount to the August 21 closing price
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release and financial schedules furnished as Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Keith Newton transitions to Executive Chairman on November 1, 2026
- President and CFO Matthew DiCanio becomes President and CEO and joins the Board as a Class III director
Item 8.01: Other Events
- Cash dividend of $0.0625 per share declared on August 5, 2026
- Record date August 20, 2026, establishing shareholder eligibility
Item 7.01: Regulation FD Disclosure
- Investor presentation covers Concentra’s second-quarter results ended June 30, 2026
- Published August 6, 2026 alongside the earnings press release
AI summaries of CON 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CON
Don't miss the next CON filing
- Alerts as it files. A push when CON files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CON, by share count.
- Ask anything. An AI agent that reads every CON filing and answers with sources.
CON alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| ORTENZIO ROBERT A | D | Aug 21, 2026 | 770,000 | $34.65 |
| ORTENZIO ROBERT A | D | Aug 21, 2026 | 20,000 | $34.65 |
| ORTENZIO ROBERT A | D | Aug 21, 2026 | 770,000 | $34.65 |
| ORTENZIO ROBERT A | D | Aug 21, 2026 | 150,000 | $34.65 |
| ORTENZIO ROBERT A | D | Aug 21, 2026 | 30,000 | $34.65 |
| ORTENZIO ROBERT A | D | Aug 21, 2026 | 30,000 | $34.65 |
| ORTENZIO ROBERT A | Sell | Aug 3, 2026 | 130,000 | $31.84 |
| ORTENZIO ROBERT A | Sell | Jul 1, 2026 | 130,000 | $30.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.9B | $2.2B |
| Operating Income | - | $304.8M | $334.0M |
| Net Income | $179.9M | $166.5M | $166.4M |
| Op. Margin | - | 16.0% | 15.4% |
| Net Margin | - | 8.8% | 7.7% |
| Balance Sheet | |||
| Total Assets | $2.3B | $2.5B | $2.9B |
| Equity | - | $275.7M | $393.3M |
| ROE | - | 60.4% | 42.3% |
| Per Share | |||
| EPS | $1.73 | $1.46 | $1.30 |
| Cash Flow | |||
| Operating CF | - | $274.7M | $279.4M |
| CapEx | $65.0M | $64.3M | $82.3M |
Source: XBRL data in Concentra Group Holdings Parent, Inc. (CON)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CON share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $2.10B |
| Q1 2026 | 32 | $1.50B |
| Q4 2025 | 28 | $1.42B |
| Q3 2025 | 31 | $1.59B |
| Q2 2025 | 30 | $1.42B |
| Q1 2025 | 27 | $781.3M |
| Q4 2024 | 22 | $574.4M |
| Q3 2024 | 12 | $43.2M |
- BlackRock+686.4K (+4%)
- T. Rowe Price Group+678.4K (+4%)
- Millennium Management+512.1K (+215%)
- Invesco Ltd+255.7K (+10%)
- State Street Corp+237.3K (+5%)
- Citadel Advisors LLC−1.08M (-88%)
- Goldman Sachs Group−389.6K (-50%)
- JPMorgan Chase & Co−239.3K (-8%)
- Bank of America Corp−157.7K (-21%)
- Morgan Stanley−106.8K (-11%)
- Blackstone Group−235.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 213 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CON filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 8-K | Aug 27, 2026 | - | Analysis | - |
| 4 | Aug 25, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 10, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 14, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 8-K | Jan 28, 2026 | - | - | |
| 8-K | Jan 12, 2026 | - | - | |
| 4 | Dec 18, 2025 | - | - | |
| 4 | Dec 1, 2025 | - | - | |
| 4 | Dec 1, 2025 | - | - | |
| 4 | Dec 1, 2025 | - | - | |
| 4 | Dec 1, 2025 | - | - | |
| 4 | Dec 1, 2025 | - | - |
Related Health Care companies
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
CON SEC filings: frequently asked questions
Are CON insiders buying or selling?
In the last 90 days, Concentra Group Holdings Parent, Inc. (CON) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $4.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CON stock?
As of June 30, 2026, the largest Concentra Group Holdings Parent, Inc. (CON) holders among the 13F filers tracked by SignalX were BlackRock ($528.2 million), T. Rowe Price Group ($527.0 million), Vanguard Portfolio Management LLC ($202.8 million), Vanguard Capital Management LLC ($152.6 million), State Street Corp ($144.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CON's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Concentra Group Holdings Parent, Inc. (CON) reported revenue of $2.2 billion (up 13.9% from FY2024) and net income of $166.4 million. Diluted EPS was $1.30. The figures come from the XBRL data in the 10-K.
What are the main risks in CON's latest 10-K?
In the 10-K filed February 26, 2026, Concentra Group Holdings Parent, Inc. (CON) flagged: Regulatory/legal risk: Non-compliance with Credit Agreement leverage covenant could trigger default, accelerate $942.9M Term Loan due 2031, and restrict borrowings under $450M Revolving Credit Facility. Macroeconomic threat: Inflation-driven labor cost increases in healthcare sector may pressure margins, though impact to date reported as not material. (AI summary of the Risk Factors section.)
What did CON report in its latest 8-K?
Concentra Group Holdings Parent, Inc. (CON) filed an 8-K on September 8, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). CEO succession effective November 1, 2026: Matthew DiCanio becomes CEO and Keith Newton becomes Executive Chairman.
What are the latest CON SEC filings?
Concentra Group Holdings Parent, Inc. (CON) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on September 1, 2026.
What is CON's SEC CIK number?
Concentra Group Holdings Parent, Inc. (CON)'s SEC Central Index Key (CIK) is 2014596. EDGAR lists every CON filing under that number.
Ask anything about CON
The research agent reads CON's filings, financials, insider trades and 13F holders, then answers with sources.